Balanced news tone
News Sentiment
ALPN sentiment intelligence
Alpine Select AG news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
54
Balanced news tone
8 relevant articles
News tone and price action are not far from neutral.
81/100 classification confidence.
directly relevant articles
high-authority source matches
+0.0% over one week, +3.3% over four weeks, trend active, and near fair-value range.
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
Market Reaction
Balanced read
News tone and price action are not far from neutral.
Primary event
Market update
81/100 classification
One-week reaction
0.0%
Price digesting
Trend fit
Trend active
3.3% over four weeks
Fair value
24.4%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
2
Neutral
6
Negative
0
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investor's Business Daily
Direct company coverage
Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 11 Apr 2024 07:00
- Source
- Investor's Business Daily
BioWorld News
Direct company coverage
Vertex buying Alpine for $4.9B for phase III-ready IgAN asset
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 11 Apr 2024 07:00
- Source
- BioWorld News
Investopedia
Direct company coverage
Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch
- Tone
- Positive 66/100
- Event
- Deals and strategy
- Published
- 10 Apr 2024 07:00
- Source
- Investopedia
Stock Titan
Direct company coverage
Vertex Enters Into Agreement to Acquire Alpine Immune Sciences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2024 07:00
- Source
- Stock Titan
Endpoints News
Direct company coverage
Vertex strikes $4.9B deal for Alpine, expanding work in kidney and autoimmune disease
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 10 Apr 2024 07:00
- Source
- Endpoints News
BioSpace
Direct company coverage
Alpine Immune Sciences Shares Updated Clinical Data from Povetacicept in IgA Nephropathy
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2024 07:00
- Source
- BioSpace
Genetic Engineering and Biotechnology News
Direct company coverage
Vertex to Acquire Alpine Immune Sciences for $4.9B, Broadening Kidney Drug Pipeline
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Apr 2024 07:00
- Source
- Genetic Engineering and Biotechnology News
Business Wire
Direct company coverage
Alpine Immune Sciences Announces Pricing of $150 Million Public Offering
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 06 Nov 2023 08:00
- Source
- Business Wire